Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI
Authors:
Open Access
- 10 January 2023
- journal article
- research article
- Published by Elsevier in JACC: Asia
- Vol. 3 (1) , 31-46
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding RiskCirculation, 2019
- Ticagrelor with or without Aspirin in High-Risk Patients after PCINew England Journal of Medicine, 2019
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIJAMA, 2019
- Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary InterventionJAMA, 2019
- Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding RiskEuropean Heart Journal, 2019
- Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trialThe Lancet, 2018
- Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCIJACC, 2016
- World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCINature Reviews Cardiology, 2014
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJACC, 1988